1. Home
  2. LTBR vs STTK Comparison

LTBR vs STTK Comparison

Compare LTBR & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

N/A

Current Price

$8.29

Market Cap

575.6M

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$7.35

Market Cap

683.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LTBR
STTK
Founded
1992
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
575.6M
683.8M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
LTBR
STTK
Price
$8.29
$7.35
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$10.00
AVG Volume (30 Days)
874.6K
863.0K
Earning Date
04-27-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.02
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.92
$0.92
52 Week High
$31.34
$8.33

Technical Indicators

Market Signals
Indicator
LTBR
STTK
Relative Strength Index (RSI) 48.04 53.84
Support Level $6.92 $6.75
Resistance Level $8.65 $7.75
Average True Range (ATR) 0.50 0.45
MACD -0.06 -0.03
Stochastic Oscillator 33.41 46.54

Price Performance

Historical Comparison
LTBR
STTK

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: